Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

944 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers.
Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KP, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones B. Willis S, et al. JCO Precis Oncol. 2017 Oct 13;1:PO.17.00009. doi: 10.1200/PO.17.00009. eCollection 2017. JCO Precis Oncol. 2017. PMID: 32913979 Free PMC article.
Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab.
Willis S, Polydoropoulou V, Sun Y, Young B, Tsourti Z, Karlis D, Long B, Lin X, Theel S, Carlson J, Győrffy B, Williams C, Abramovitz M, Dafni U, Dowsett M, Leyland-Jones B. Willis S, et al. JCO Precis Oncol. 2018 Nov 1;2:PO.18.00016. doi: 10.1200/PO.18.00016. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32913993 Free PMC article.
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B. Loi S, et al. Among authors: willis s. JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339. JAMA Oncol. 2016. PMID: 27100299
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B. Willis S, et al. PLoS One. 2016 Feb 17;11(2):e0149183. doi: 10.1371/journal.pone.0149183. eCollection 2016. PLoS One. 2016. PMID: 26886260 Free PMC article.
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
Buechler SA, Gray KP, Gökmen-Polar Y, Willis S, Thürlimann B, Kammler R, Viale G, Leyland-Jones B, Badve SS, Regan MM. Buechler SA, et al. Among authors: willis s. JNCI Cancer Spectr. 2019 Aug 16;3(4):pkz051. doi: 10.1093/jncics/pkz051. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337480 Free PMC article.
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.
Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, Foekens JA, Harris RS, Martens JW. Sieuwerts AM, et al. Among authors: willis s. Horm Cancer. 2014 Dec;5(6):405-13. doi: 10.1007/s12672-014-0196-8. Epub 2014 Aug 15. Horm Cancer. 2014. PMID: 25123150 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33574291
944 results